Moreover, in c-KIT-mutant acral melanoma, the addition of TKIs targeting MET and KIT showed increased efficacy compared to KIT alone in the presence of hepatocyte growth factor, the ligand for MET [150]. This evidence concerns the gene KIT and acral lentiginous melanoma.